Skip to content

INOZYME PHARMA, INC.

CIK 0001693011

← back to feed
Revenue (TTM)
—
Q1 Apr 2025
Net Income (TTM)
−$102.99M
−43.4% YoY Q1 Apr 2025
EPS Diluted (TTM)
−$1.65
−18.2% YoY Q1 Apr 2025
Gross Margin
—
Q1 Apr 2025
Operating Margin
—
Q1 Apr 2025
Net Margin
—
Q1 Apr 2025
Free Cash Flow (TTM)
−$85.84M
Q1 Apr 2025
Cash
$25.85M
Q1 Apr 2025
Total Debt
$46.29M
Q1 Apr 2025
Shares Outstanding
64.56M sh
Q1 Apr 2025

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings